Drug-specific effect of nelfinavir and stavudine on primary culture of human preadipocytes

Journal of Acquired Immune Deficiency Syndromes

Volumn 48, Issue 1, 2008, Pages 20-25

  Saillan Barreau, Corinne ^a,b   Tabbakh, Oumaima ^a,b   Chavoin, Jean Pierre ^c   Casteilla, Louis ^a,b   Pénicaud, Luc ^a,b  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b CNRS   (France)

^c CHU RANGUEIL   (France)

Author keywords

Human adipocyte; Lamin; Lipodystrophy; Mitochondria; Nelfinavir; Stavudine

Indexed keywords

NELFINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROADIPOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADIPOCYTES; BASE SEQUENCE; CELL DIFFERENTIATION; CELLS, CULTURED; DNA PRIMERS; HUMANS; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; NELFINAVIR; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE;

EID: 42649122990     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31816b6aa4     Document Type: Article

References (35)

1. Moitra J, Mason MM, Olive M, et al. Life without white fat: a transgenic mouse. Genes Dev. 1998;12:3168-3181.
2. Garg A. Lipodystrophies. Am J Med. 2000;108:143-152.
3. Jain RG, Furfine ES, Pedneault L, et al. Metabolic complications associated with antiretroviral therapy. Antiviral Res. 2001;51:151-177.
4. Vigouroux C, Maachi M, Nguyen TH, et al. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS. 2003;17:1503-1511.
5. Gougeon ML, Penicaud L, Fromenty B, et al. Adipocytes: targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations. Antivir Ther. 2004;9:161-177.
6. Dupin N, Buffet M, Marcelin AG, et al. HIV and antiretroviral drug distribution in plasma and fat tissue of HIV-infected patients with lipodystrophy. AIDS. 2002;16:2419-2424.
7. Vernochet C, Azoulay S, Duval D, et al. Human immunodeficiency virus protease inhibitors accumulate into cultured human adipocytes and alter expression of adipocytokines. J Biol Chem. 2005;280:2238-2243.
8. Van Harmelen V, Skurk T, Hauner H. Primary culture and differentiation of human adipocyte precursor cells. Methods Mol Med. 2005;107:125-135.
9. Gagnon A, Angel JB, Sorisky A. Protease inhibitors and adipocyte differentiation in cell culture. Lancet. 1998;352:1032.
10. Zhang B, MacNaul K, Szalkowski D, et al. Inhibition of adipocyte differentiation by HIV protease inhibitors. J Clin Endocrinol Metab. 1999;84:4274-4277.
11. Lenhard JM, Furfine ES, Jain RG, et al. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Antiviral Res. 2000;47:121-129.
12. Roche R, Poizot-Martin I, Yazidi CM, et al. Effects of antiretroviral drug combinations on the differentiation of adipocytes. AIDS. 2002;16:13-20.
13. Caron M, Auclair M, Lagathu C, et al. The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro. AIDS. 2004;18:2127-2136.
14. Lagathu C, Kim M, Maachi M, et al. HIV antiretroviral treatment alters adipokine expression and insulin sensitivity of adipose tissue in vitro and in vivo. Biochimie. 2005;87:65-71.
15. Caron M, Auclair M, Vigouroux C, et al. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes. 2001;50:1378-1388.
16. Bastard JP, Caron M, Vidal H, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet. 2002;359:1026-1031.
17. Caron M, Auclair M, Sterlingot H, et al. Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS. 2003;17:2437-2444.
18. Vigouroux C, Auclair M, Dubosclard E, et al. Nuclear envelope disorganization in fibroblasts from lipodystrophic patients with heterozygous R482Q/W mutations in the lamin A/C gene. J Cell Sci. 2001;114:4459-4468.
19. Favreau C, Dubosclard E, Ostlund C, et al. Expression of lamin A mutated in the carboxyl-terminal tail generates an aberrant nuclear phenotype similar to that observed in cells from patients with Dunnigan-type partial lipodystrophy and Emery-Dreifuss muscular dystrophy. Exp Cell Res. 2003;282:14-23.
20. Lloyd DJ, Trembath RC, Shackleton S. A novel interaction between lamin A and SREBP1: implications for partial lipodystrophy and other laminopathies. Hum Mol Genet. 2002;11:769-777.
21. Cossarizza A, Mussini C, Vigano A. Mitochondria in the pathogenesis of lipodystrophy induced by anti-HIV antiretroviral drugs: actors or bystanders? Bioessays. 2001;23:1070-1080.
22. Zaera MG, Miro O, Pedrol E, et al. Mitochondrial involvement in antiretroviral therapy-related lipodystrophy. AIDS. 2001;15:1643-1651.
23. Cote HC, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med. 2002;346:811-820.
24. Hammond E, Nolan D, James I, et al. Reduction of mitochondrial DNA content and respiratory chain activity occurs in adipocytes within 6-12 months of commencing nucleoside reverse transcriptase inhibitor therapy. AIDS. 2004;18:815-817.
25. Villarroya F, Domingo P, Giralt M. Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: the adipocyte as a target of anti-retroviral-induced mitochondrial toxicity. Trends Pharmacol Sci. 2005;26:88-93.
26. Petit F, Fromenty B, Owen A, et al. Mitochondria are sensors for HIV drugs. Trends Pharmacol Sci. 2005;26:258-264.
27. Hoschele D. Cell culture models for the investigation of NRTI-induced mitochondrial toxicity. Relevance for the prediction of clinical toxicity. Toxicol In Vitro. 2006;20:535-546.
28. Deveaud C, Beauvoit B, Hagry S, et al. Site specific alterations of adipose tissue mitochondria in 3′-azido-3′-deoxythymidine (AZT)-treated rats: an early stage in lipodystrophy? Biochem Pharmacol. 2005;70:90-101.
29. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem. 2000;275:20251-20254.
30. Dowell P, Flexner C, Kwiterovich PO, et al. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. J Biol Chem. 2000;275:41325-41332.
31. Pinti M, Salomoni P, Cossarizza A. Anti-HIV drugs and the mitochondria. Biochim Biophys Acta. 2006;1757:700-707.
32. Petit C, Pietri-Rouxel F, Lesne A, et al. Oxygen consumption by cultured human cells is impaired by a nucleoside analogue cocktail that inhibits mitochondrial DNA synthesis. Mitochondrion. 2005;5:154-161.
33. Lagathu C, Eustace B, Prot M, et al. Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther. 2007;12:489-500.
34. Jones SP, Janneh O, Back DJ. Altered adipokine response murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors. Antivir Ther. 2005;10:207-213.
35. Wentworth JM, Burris TP, Chatterjee VK. HIV protease inhibitors block human preadipocyte differentiation, but not via the PPARgamma/RXR heterodimer. J Endocrinol. 2000;164:R7-R10.